{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:12:30Z","timestamp":1779199950491,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Psoriasis is a chronic systemic inflammatory skin disorder that is strongly associated with metabolic disorders, including obesity, insulin resistance, hypertension, and dyslipidemia. Dyslipidemia causes abnormalities in lipid profiles, such as elevated triglycerides or low density lipoprotein (LDL) levels. Measure maternally expressed gene 3 (MEG3) and microRNA-147b in serum of patients with and without dyslipidemia compared to healthy control. These measurements were compared with clinical characteristics, clinical parameters, and laboratory investigations. Serum expression levels of MEG3 and microRNA-147b, as non-coding RNA biomarkers, were measured across four equally subcategorized groups (patients with and without dyslipidemia (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u200966) and healthy controls with and without dyslipidemia (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u200966) using Polymerase Chain Reaction (PCR). Psoriatic patients exhibited a high significantly body mass index and elevated low-density lipoprotein levels compared with controls (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.038,0.010) respectively, while fasting blood glucose was significantl at\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.001. Fasting blood glucose and lipid parameters showed low levels in patients without dyslipidemia and high levels of high-density lipoprotein than those with dyslipidemia. Expression Level of MEG3 was significantly downregulated, whereas microRNA-147b was markedly upregulated in psoriatic patients (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001). MEG3 expression was negatively correlated with disease severity indices and lipid levels and inversely correlated with microRNA-147b, which also negatively correlated with disease duration. MEG3 and miR-147b, as non-coding RNAs, may show differential expression among psoriasis patient subgroups and could be associated with disease-related parameters, but their value as markers of disease severity or prognosis remains to be confirmed.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-52391-0","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:35:10Z","timestamp":1779197710000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Studying the expression levels of LncRNA-MEG3 and miR-147b in the serum of psoriasis patients with and without dyslipidemia"],"prefix":"10.1038","volume":"16","author":[{"given":"Marwa","family":"Kamel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rehab Elsayed","family":"Marzouk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olfat G.","family":"Shaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed Ali","family":"Gameil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmine M.","family":"Amrousy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esraa","family":"Farag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanan M.","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amal","family":"Wagdy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laila","family":"Mahdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"52391_CR1","first-page":"101030","volume":"26","author":"AM Elamir","year":"2021","unstructured":"Elamir, A. M., Shaker, O. G., El-Komy, M. H., Sharabi, M. M. & Aboraia, N. M. The role of LncRNA MALAT-1 and MiRNA-9 in psoriasis. Biochem. Biophys. Res. Commun. 26, 101030 (2021).","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"52391_CR2","first-page":"15","volume":"5","author":"S Ghafouri-Fard","year":"2020","unstructured":"Ghafouri-Fard, S., Shoorei, H. & Taheri, M. The eminent roles of non-coding RNAs in the pathogenesis of psoriasis. Non-coding RNA Res. 5 (1), 15\u201327 (2020).","journal-title":"Non-coding RNA Res."},{"issue":"1","key":"52391_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4078\/jrd.2025.0074","volume":"33","author":"GG Maghraby","year":"2026","unstructured":"Maghraby, G. G. et al. Genetic and epigenetic insights into systemic lupus erythematosus: linking long non-coding RNA growth arrest-specific transcript 5 and interferon signature. J. rheumatic Dis. 33 (1), 55\u201364 (2026).","journal-title":"J. rheumatic Dis."},{"key":"52391_CR4","doi-asserted-by":"publisher","first-page":"155853","DOI":"10.1016\/j.cyto.2022.155853","volume":"153","author":"ZL Tang","year":"2022","unstructured":"Tang, Z. L., Zhang, K., Lv, S. C., Xu, G. W. & Zhang, J. F. LncRNA MEG3 suppresses PI3K\/AKT\/mTOR signalling to enhance autophagy and inhibit inflammation in TNF-\u03b1-treated keratinocytes and psoriatic mice. Cytokine 153, 155853 (2022).","journal-title":"Cytokine"},{"key":"52391_CR5","doi-asserted-by":"crossref","unstructured":"Ghafouri-Fard, S. & Taheri, M. Maternally expressed gene 3 (MEG3): A tumor suppressor long non coding RNA. Biomed. Pharmacother. 118, 109129 (2019).","DOI":"10.1016\/j.biopha.2019.109129"},{"key":"52391_CR6","first-page":"109","volume":"158","author":"A Chandra","year":"2023","unstructured":"Chandra, A. et al. Serum miRNA profiling identifies miRNAs associated with disease severity in psoriasis. Mol. Immunol. 158, 109\u2013118 (2023).","journal-title":"Mol. Immunol."},{"issue":"2","key":"52391_CR7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1055\/s-0040-1722104","volume":"57","author":"J Charan","year":"2021","unstructured":"Charan, J. et al. Sample size calculation in medical research: A primer. Annals Natl. Acad. Med. Sci. 57 (2), 74\u201380 (2021).","journal-title":"Annals Natl. Acad. Med. Sci."},{"key":"52391_CR8","doi-asserted-by":"crossref","unstructured":"Mease, P. J. Measures of psoriatic arthritis: Tender and swollen joint assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander\/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res. (Hoboken) ). 63(Suppl 11), S64\u2013S85 (2011).","DOI":"10.1002\/acr.20577"},{"issue":"1","key":"52391_CR9","doi-asserted-by":"publisher","first-page":"30537","DOI":"10.1038\/s41598-024-81212-5","volume":"14","author":"NR Mohamed","year":"2024","unstructured":"Mohamed, N. R., El-Fattah, A. L. A., Shaker, O. & Sayed, G. A. The diagnostic and predictive potential of lncRNA CASC2 targeting miR-155 in systemic lupus erythematosus patients with nephritis complication. Sci. Rep. 14 (1), 30537 (2024).","journal-title":"Sci. Rep."},{"issue":"4","key":"52391_CR10","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00251-024-01346-8","volume":"76","author":"S Abobakr","year":"2024","unstructured":"Abobakr, S., Shaker, O., Hegazy, M. T. & Hany, A. M. A possible role of lncRNA MEG3 and lncRNA MAFG-AS1 on miRNA 147-b in the pathogenesis of Behcet\u2019s disease. Immunogenetics 76 (4), 233\u2013241 (2024).","journal-title":"Immunogenetics"},{"key":"52391_CR11","doi-asserted-by":"publisher","first-page":"1174998","DOI":"10.3389\/fimmu.2023.1174998","volume":"14","author":"ZY Zhang","year":"2023","unstructured":"Zhang, Z. Y., Jian, Z. Y., Tang, Y. & Li, W. The relationship between blood lipid and risk of psoriasis: univariable and multivariable Mendelian randomization analysis. Front. Immunol. 14, 1174998 (2023).","journal-title":"Front. Immunol."},{"issue":"1","key":"52391_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12944-024-02123-y","volume":"23","author":"C Zhang","year":"2024","unstructured":"Zhang, C., Dong, X., Chen, J. & Liu, F. Association between lipid accumulation product and psoriasis among adults: a nationally representative cross-sectional study. Lipids Health Dis. 23 (1), 143 (2024).","journal-title":"Lipids Health Dis."},{"issue":"5","key":"52391_CR13","first-page":"1234","volume":"15","author":"A Gosai","year":"2024","unstructured":"Gosai, A., Sao, R. & Mahaseth, B. K. A study of dyslipidemia in psoriasis patients: A case-control study. J. Cardiovasc. Disease Res. 15 (5), 1234\u20131242 (2024).","journal-title":"J. Cardiovasc. Disease Res."},{"issue":"9","key":"52391_CR14","first-page":"612","volume":"15","author":"B Patel","year":"2025","unstructured":"Patel, B., Kalal, L. & Patel, Y. J. Dyslipidemia and its correlation with psoriasis severity: A case-control study. Eur. J. Cardiovasc. Med. 15 (9), 612\u2013618 (2025).","journal-title":"Eur. J. Cardiovasc. Med."},{"issue":"11","key":"52391_CR15","first-page":"e49241","volume":"15","author":"JA Alshahrani","year":"2023","unstructured":"Alshahrani, J. A. et al. A Holistic View of Psoriasis: Examining Its Association With Dyslipidemia and Obesity in a Decade-Long Systematic Review and Meta-Analysis. Cureus 15 (11), e49241 (2023).","journal-title":"Cureus"},{"issue":"4","key":"52391_CR16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00251-024-01346-8","volume":"76","author":"S Abobakr","year":"2024","unstructured":"Abobakr, S., Shaker, O., Hegazy, M. T. & Hany, A. M. A possible role of lncRNA MEG3 and lncRNA MAFG-AS1 on miRNA 147-b in the pathogenesis of Beh\u00e7et\u2019s disease. Immunogenetics 76 (4), 233\u2013241 (2024).","journal-title":"Immunogenetics"},{"key":"52391_CR17","doi-asserted-by":"publisher","first-page":"1608902","DOI":"10.3389\/fcell.2025.1608902","volume":"13","author":"S Li","year":"2025","unstructured":"Li, S. et al. miRNAs and exosomes in psoriasis: coordinating cytoskeleton dynamics and extracellular matrix remodeling. Front. Cell. Dev. Biology. 13, 1608902 (2025).","journal-title":"Front. Cell. Dev. Biology"},{"key":"52391_CR18","doi-asserted-by":"crossref","unstructured":"Rajendran, A., Harikumar, M. V. & Swaminathan, A. Lipid abnormalities and electrocardiographic changes in patients with psoriasis in a tertiary care hospital. Cureus, 17(4), e82164. (2025).","DOI":"10.7759\/cureus.82164"},{"issue":"3","key":"52391_CR19","first-page":"451","volume":"56","author":"SA Jasim","year":"2025","unstructured":"Jasim, S. A., Abbas, M., Mustafa, E. T. & Khalid, A. S. Correlation between psoriasis severity and dyslipidaemia in Iraqi patients. Scripta Med. 56 (3), 451\u2013459 (2025).","journal-title":"Scripta Med."},{"key":"52391_CR20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12860-019-0229-9","volume":"20","author":"HY Jia","year":"2019","unstructured":"Jia, H. Y. et al. LncRNA MEG3 influences the proliferation and apoptosis of psoriasis epidermal cells by targeting miR\u201321\/caspase\u20138. BMC Mol. Cell. Biology. 20, 46 (2019).","journal-title":"BMC Mol. Cell. Biology"},{"key":"52391_CR21","unstructured":"Elmasry, M. F. et al. Possible role of lncRNA MEG3\u2013microRNA\u201321 and endoplasmic reticulum stress proteins in the pathogenesis of psoriasis vulgaris (EADV, 2023)."},{"issue":"4","key":"52391_CR22","first-page":"619","volume":"53","author":"Q Dong","year":"2023","unstructured":"Dong, Q., Liang, G. T., Li, J. & Chen, H. Role of MEG3 in cellular physiology of atherosclerosis. Annals Clin. Lab. Sci. 53 (4), 619\u2013629 (2023).","journal-title":"Annals Clin. Lab. Sci."},{"key":"52391_CR23","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41420-025-02389-w","volume":"11","author":"J Zhou","year":"2025","unstructured":"Zhou, J., Tian, X., Li, W. & Zhang, Y. LncRNA MEG3 up\u2013regulates SIRT6 by ubiquitinating EZH2 and alleviates non-alcoholic fatty liver disease. Cell. Death Discovery. 11, 112 (2025).","journal-title":"Cell. Death Discovery"},{"issue":"4","key":"52391_CR24","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00251-024-01346-8","volume":"76","author":"S Abobakr","year":"2024","unstructured":"Abobakr, S., Shaker, O., Hegazy, M. T. & Hany, A. M. A possible role of lncRNA MEG3 and lncRNA MAFG-AS1 on miRNA 147-b in the pathogenesis of Behcet\u2019s disease. Immunogenetics 76 (4), 233\u2013241 (2024).","journal-title":"Immunogenetics"},{"issue":"3","key":"52391_CR25","first-page":"1131","volume":"48","author":"P Zhang","year":"2019","unstructured":"Zhang, P., Fan, H., Zhang, C. & Zeng, C. LncRNA MEG3 functions as a ceRNA in regulating hepatic lipogenesis by competitively binding to miR\u201321 with LRP6. Cell. Physiol. Biochem. 48 (3), 1131\u20131142 (2019).","journal-title":"Cell. Physiol. Biochem."},{"key":"52391_CR26","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41420-022-00925-6","volume":"8","author":"X Zhao","year":"2022","unstructured":"Zhao, X., Li, S., Yang, X. & Zhou, Y. LncRNA MEG3 up\u2013regulates SIRT6 by ubiquitinating EZH2 and alleviates nonalcoholic fatty liver disease. Cell. Death Discovery. 8, 164 (2022).","journal-title":"Cell. Death Discovery"},{"key":"52391_CR27","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1007\/s11695-024-07302-5","volume":"34","author":"K Qureshi","year":"2024","unstructured":"Qureshi, K. & Adabala, V. Expression and relations of circulating microRNAs in metabolic syndrome: a systematic review. Obes. Surg. 34, 3038\u20133057 (2024).","journal-title":"Obes. Surg."},{"key":"52391_CR28","unstructured":"Saribuluk, E., Kilic, E., Ozturk, F., Ozcan, T. & Kilic, G. Clinical association and diagnostic significance of miRNA\u201329a and miRNA\u2013147b in type 2 diabetes mellitus. J. Clin. Lab. Anal. 37(2), e37786444 (2023)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52391-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52391-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52391-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:47:12Z","timestamp":1779198432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52391-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["52391"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-52391-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Medical Research Ethics Committee, Institutional Review Board (IRB), Faculty of Medicine, Mansoura University, with approval code R.25.07.3264 on 25\/08\/2025.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The content has not been published, nor has submitted for publication elsewhere.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"15509"}}